Agricultural chemicals maker Corteva is getting a break from cheap generic competition, but a new headache is forming: rising raw-material costs that could pressure results into 2027, according to UBS.
The bank kept its neutral rating on the stock and trimmed its price target to $15, with shares trading around $13.07 at the time of the note. The message is that Corteva's near-term fortunes hinge on how quickly it can pass higher costs on to customers without losing volume.
Generic pressure easing, but costs rising
Crop-chemical makers have spent the past few years fighting a price war as generic products from China and India grabbed market share. UBS believes that pressure is finally starting to ease. But the bank sees a new problem taking its place: higher input costs, driven by commodity inflation, that could climb through 2027.
That matters because Corteva can't always reprice instantly. In this industry, price lists and customer contracts often reset around seasonal selling cycles, so costs can rise in the income statement before higher prices show up in revenue. That timing mismatch is at the heart of UBS's cautious stance.
UBS's base case reflects that tension: less than 1% annual price increases, volume growth of 2.5% to 3%, and roughly 3% organic growth through 2029. The bank sees meaningful help from new products more likely in 2028 and beyond, meaning the next one to two years look like a margin test.
What it means for investors
For investors, the key swing factor is gross margin—the gap between what Corteva sells its products for and what they cost to make. If input costs keep rising while prices tick up only slowly, that gap could shrink. The question is how quickly Corteva can pass costs on without losing market share.
UBS's $15 target suggests the stock is fairly valued at current levels, with limited upside unless there's clearer evidence of cost pass-through. The bank's neutral rating implies that better demand or market-share gains alone may not be enough to lift expectations.
This kind of cost-price squeeze is a common theme across industries right now. US staples demand has steadied, but input costs cloud the 2027 outlook, according to BofA. Similarly, Valmont's utility pricing gains are pacing, but costs still bite. Even Delta cut its 2026 profit forecast as jet fuel costs surged, showing how widespread input-cost inflation has become.
For Corteva, the next few quarters will be a test of its pricing power. If it can pass costs through quickly, margins may hold up better than expected. If not, the stock could stay stuck near its current level until the picture clears.
Investors should watch for any signs of the cost lag shrinking or widening in upcoming earnings reports. That will be the clearest signal of whether Corteva can navigate this tricky period.
